APLT APPLIED THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2025, APPLIED THERAPEUTICS INC reported revenue of $1.00M (up 719.7% from a year earlier), net income of −$19.0M and diluted EPS of −$0.13; over the last four quarters revenue was $999K and net income −$18.1M; for the fiscal year ended December 2024 revenue was $455K, down 95.4% on the year before.
APLT annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $455K, gross profit n/a, operating income −$104M, net income −$106M (margin -23214.1%), EPS −$0.76
- Fiscal year ended Dec 2023: revenue $9.99M, gross profit n/a, operating income −$64.5M, net income −$120M (margin -1198.5%), EPS −$1.42
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$83.0M, net income −$82.5M (margin n/a), EPS −$2.18
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$106M, net income −$106M (margin n/a), EPS −$4.12
APLT quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $1.00M (up 719.7% year over year), net income −$19.0M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$21.3M, EPS −$0.15
- Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$21.8M, EPS −$0.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue −$1.00K, net income $44.0M, EPS $0.52
- Quarter ended Sep 30, 2024: revenue $122K, net income −$68.6M, EPS −$0.48
- Quarter ended Jun 30, 2024: revenue $144K, net income $2.90M, EPS −$0.13
- Quarter ended Mar 31, 2024: revenue $190K (down 98.2% year over year), net income −$83.9M, EPS −$0.67
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$37.7M, EPS −$0.40
- Quarter ended Sep 30, 2023: revenue n/a, net income −$42.4M, EPS −$0.47
- Quarter ended Jun 30, 2023: revenue n/a, net income −$29.6M, EPS −$0.37
- Quarter ended Mar 31, 2023: revenue $10.7M, net income −$10.1M, EPS −$0.18
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$14.4M, EPS $0.06
- Quarter ended Sep 30, 2022: revenue n/a, net income −$19.1M, EPS −$0.40
- Quarter ended Jun 30, 2022: revenue n/a, net income −$25.9M, EPS −$0.96
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.1M, EPS −$0.88
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$27.2M, EPS −$1.04
- Quarter ended Sep 30, 2021: revenue n/a, net income −$28.4M, EPS −$1.09
- Quarter ended Jun 30, 2021: revenue n/a, net income −$25.8M, EPS −$0.99
- Quarter ended Mar 31, 2021: revenue n/a, net income −$24.2M, EPS −$1.00
APLT cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$84.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$55.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$78.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$90.7M, share buybacks n/a
APLT balance sheet
- Sep 30, 2025: cash $11.9M, total assets $34.4M, total liabilities $34.9M, shareholders' equity −$561K
- Jun 30, 2025: cash $30.4M, total assets $37.3M, total liabilities $19.9M, shareholders' equity $17.4M
- Mar 31, 2025: cash $50.8M, total assets $56.9M, total liabilities $20.2M, shareholders' equity $36.7M
- Dec 31, 2024: cash $79.4M, total assets $86.7M, total liabilities $29.7M, shareholders' equity $57.0M
- Sep 30, 2024: cash $98.9M, total assets $107M, total liabilities $101M, shareholders' equity $5.89M
- Jun 30, 2024: cash $122M, total assets $128M, total liabilities $55.4M, shareholders' equity $72.4M
- Mar 31, 2024: cash $146M, total assets $151M, total liabilities $83.9M, shareholders' equity $67.3M
- Dec 31, 2023: cash $49.9M, total assets $54.8M, total liabilities $72.0M, shareholders' equity −$17.1M
What is APLT's revenue?
APPLIED THERAPEUTICS INC reported $999K of revenue over its last four quarters, through September 30, 2025.
Is APLT profitable?
No. APPLIED THERAPEUTICS INC lost $18.1M over the last four quarters.
What is APLT's EPS?
Diluted earnings per share over the last four quarters were $0.09; −$0.13 in the latest quarter.